Phase 2 N=40 Antineoplaston Therapy in Treating Adults With Residual/Recurrent/Progressive Glioblastoma Multiforme
Glioblastoma Multiforme of the Brain
Primary: Number of Participants With Objective Response — 1; 1; 5; 19 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=11 Phase II Feasibility Study of Dendritic Cell Vaccination for Newly Diagnosed Glioblastoma Multiforme
Glioblastoma Multiforme
Primary: Tumor-specific Cytotoxic T-cell Response — 0.496; 0.4836 10^9 cells/L
N/A N=20 Molecular Profiling in Guiding Individualized Treatment Plan in Adults With Recurrent/Progressive Glioblastoma
Adult Glioblastoma
Primary: Number of Participants Who Received Treatment Recommendations Within 35 Days of Surgery — 15 Participants
Phase 3 N=562 Radiation Therapy With or Without Temozolomide in Treating Older Patients With Newly Diagnosed Glioblastoma Multiforme
Brain and Central Nervous System Tumors
Primary: Overall Survival — 9.33; 7.62 Months
Phase 2 N=31 Low Dose Radiation Therapy for Glioblastoma Multiforme
High Grade Glioma
Primary: Response Rate
Phase 2 N=40 Antineoplaston Therapy in Treating Patients With Newly-diagnosed Glioblastoma Multiforme
Glioblastoma Multiforme of Brain
Primary: Number of Participants With Objective Response — 2; 1; 2; 27 Participants
Phase 2 N=31 Repeated Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Newly Diagnosed GBM
Glioblastoma Multiforme · Brain Tumor
Primary: Progression-free Survival (PFS) — 91.3 percentage of participants
Phase 2 N=72 Gliadel Wafer and Fluorescence-Guided Surgery With 5-ALA Followed by Radiation Therapy And Temozolomide in Treating Patients With Primary Glioblastoma
Glioblastoma
Primary: Safety, Tolerability, and Feasibility of Combination Intra-operative 5-ALA and Gliadel Wafers Prior to Adjuvant Radiotherapy Plus Temozolomide — 62; 9; 6; 45 Participants
Phase 2 N=10 Nivolumab, Ipilimumab, and Short-course Radiotherapy in Adults With Newly Diagnosed, MGMT Unmethylated Glioblastoma
MGMT-unmethylated Glioblastoma (GBM) · GBM
Primary: 1-year Overall Survival (OS) — 80 percentage of participants
Phase 2 N=47 Convection-Enhanced Delivery (CED) of MDNA55 in Adults With Recurrent or Progressive Glioblastoma
Glioblastoma · Grade IV Astrocytoma · Glioblastoma Multiforme
Primary: Overall Survival (OS) — 10.2; 11.64 months
Phase 2 N=18 CAR T Cell Receptor Immunotherapy Targeting EGFRvIII for Patients With Malignant Gliomas Expressing EGFRvIII
Malignant Glioma · Glioblastoma · Brain Cancer
Primary: Number of Treatment Related Adverse Events — 0; 0; 0; 0 adverse events
Phase 2 N=35 Stereotactic Radiosurgery and Radiation Therapy in Treating Patients With Glioblastoma Multiforme
Brain and Central Nervous System Tumors
Primary: Overall Survival After Treatment — 15.8; 22; 18.7; 12.5 months
Phase 1 N=16 Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas
Adult Anaplastic Astrocytoma · Adult Anaplastic Oligodendroglioma · Adult Giant Cell Glioblastoma
Primary: Number of Participants With Dose Limiting Toxicities (DLTs) and Maximum Tolerated Dose (MTD) — 0; 0; 0; 1 Participants
Phase 2 N=20 Autologous CMV-Specific Cytotoxic T Cells and Temozolomide in Treating Patients With Glioblastoma
Cytomegalovirus Positive · Glioblastoma · Gliosarcoma
Primary: Maximum Tolerated Dose (MTD) (Recurrent Glioblastoma Participant Cohort)- Phase I — 3; 3; 3; 7 participants
Phase 2 N=20 Phase II NKTR-102 In Bevacizumab-Resistant High Grade Glioma
Anaplastic Astrocytomas · Anaplastic Oligodendrogliomas · Glioblastomas (GBM)
Primary: Progression Free Survival, Assessed by Revised Assessment in Neuro-oncology (RANO) Criteria — 11 participants
Phase 2 N=39 Phase 2 Study of Sym004 for Adult Patients With Recurrent Glioblastoma
Malignant Glioma
Primary: Six-month Progression-free Survival (PFS6) — 14.3; 5; 14.3; 40 percentage of participants
Phase 2 N=222 Study of XL184 (Cabozantinib) in Adults With Glioblastoma Multiforme
Glioblastoma Multiforme
Primary: Objective Response Rate (ORR) — 17.6; 27.0; 8.8; 8.3 percentage of participants
Phase 2 N=5 Vaccine for Patients With Newly Diagnosed or Recurrent Low-Grade Glioma
Adult Diffuse Astrocytoma · Adult Mixed Glioma · Adult Oligodendroglioma
Primary: Progression-free Survival (PFS) of Low Grade Glioma Patients Treated With Autologous Dendritic Cells Pulsed With Autologous Tumor Lysate — 0; 1; 1; 1 participants
Phase 2 N=124 A Study of ICT-107 Immunotherapy in Glioblastoma Multiforme (GBM)
Glioblastoma Multiforme
Primary: Overall Survival (OS) — 18.3; 16.7 months of survival
Phase 2 N=154 Vaccine Therapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme
Glioblastoma Multiforme · Glioblastoma · Malignant Glioma
Primary: Comparison of Overall Survival (OS) Between the Active Treatment Group (Arms 1 and 2) and the Control Group (Arm 3) — 16.9; 16.2; 20.6 months — p=0.196
Phase 1 N=11 Cytomegalovirus (CMV) RNA-Pulsed Dendritic Cells for Pediatric Patients and Young Adults With WHO Grade IV Glioma, Recurrent Malignant Glioma, or Recurrent Medulloblastoma
Glioblastoma · Malignant Glioma · Medulloblastoma Recurrent
Primary: Percentage of Patients for Whom 3 or More Vaccines Can be Made — 90.9 percentage of participants
Phase 2 N=158 A Study in Recurrent Glioblastoma (GB)
Glioblastoma
Primary: Overall Survival (OS) — 8.0; 6.7; 7.5 Months
Phase 3 N=1,125 Radiation Therapy (RT) and Temozolomide (TMZ) in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma
Brain and Central Nervous System Tumors
Primary: Median Overall Survival Time — 16.6; 14.9 months — p=0.63
Phase 2 N=17 Whole Brain Radiation Therapy With Standard Temozolomide Chemo-Radiotherapy and Plerixafor in Treating Patients With Glioblastoma
Glioblastoma · Glioblastoma With Primitive Neuronal Component · Gliosarcoma
Primary: Proportion of Progression Free Survival Participants (PFS) at Six Months — 0.786 Proportion of participants
Phase 1 N=3 Neural Stem Cell Based Virotherapy of Newly Diagnosed Malignant Glioma
Glioma · Anaplastic Astrocytoma · Anaplastic Oligodendroglioma
Primary: Percentage of Dose-limiting Toxicities — 0; 0; 17 Percentage of dose-limiting toxicities
Phase 2 N=44 GDC-0449 in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery
Adult Giant Cell Glioblastoma · Adult Glioblastoma · Adult Gliosarcoma
Primary: 6 Months Progression-free Survival (PFS) — 0; 5 percentage of patients
Phase 2 N=88 Bevacizumab for Recurrent Malignant Glioma
Recurrent High-Grade Gliomas · Malignant Gliomas
Primary: Percentage of Participants With Progression Free Survival at 6 Months. — 20.9; 29 Percentage of participants
Phase 2 N=80 Ramucirumab or Anti-PDGFR Alpha Monoclonal Antibody IMC-3G3 in Treating Patients With Recurrent Glioblastoma Multiforme
Adult Glioblastoma Multiforme
Primary: Percentage of Participants Who Achieved Progression-Free Survival Rate at 6 Months (PFS-6) — 12.5; 7.5 percentage of participants
Phase 2 N=151 A Study in Subjects With Recurrent Malignant Glioma
Glioma
Primary: Progression Free Survival (PFS) Rate at Month 6 — 11.0; 21.2; 8.0; 7.6 Percentage of participants
Phase 2 N=97 Radiation Therapy and Temozolomide Followed by Temozolomide and Poly ICLC in Treating Patients With Newly Diagnosed GBM
Glioblastoma Multiforme
Primary: Survival — 17.2 months — p=>.1